200
Participants
Start Date
May 5, 2025
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
Tappt
"Tappt is a web-based system designed to record participants medication taking behavior and bowel symptoms. Participants will be assigned smart labels for their specific vedolizumab regimen, which will be used by participants to record their vedolizumab use. Participants will be shipped smart labels to be affixed to an IV card for the first three infusions and for subsequent infusions or injections. At the time of a vedolizumab dose, participants will scan the smart label by tapping it with their mobile device to verify that they are taking the medication. Each day that vedolizumab is due, patients will receive a reminder through SMS message. If participants fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message reminder. Participants will also complete a patient reported outcome assessment at baseline, weekly for 6 weeks, and then monthly for the entire 22 weeks of the study triggered by the system."
RECRUITING
New York University, New York
NOT_YET_RECRUITING
Capital Digestive Care, Chevy Chase
RECRUITING
University of North Carolina, Chapel Hill
NOT_YET_RECRUITING
Vanderbilt University, Nashville
NOT_YET_RECRUITING
University of Cincinnati, Cincinnati
NOT_YET_RECRUITING
Tulane University, New Orleans
Lead Sponsor
Collaborators (1)
Takeda
INDUSTRY
Mercy Medical Center
OTHER